Attached files
| file | filename |
|---|---|
| EX-10.4 - EX-10.4 - Jounce Therapeutics, Inc. | a2230618zex-10_4.htm |
| EX-10.14 - EX-10.14 - Jounce Therapeutics, Inc. | a2230618zex-10_14.htm |
| EX-10.13 - EX-10.13 - Jounce Therapeutics, Inc. | a2230618zex-10_13.htm |
| EX-10.6 - EX-10.6 - Jounce Therapeutics, Inc. | a2230618zex-10_6.htm |
| EX-10.5 - EX-10.5 - Jounce Therapeutics, Inc. | a2230618zex-10_5.htm |
| EX-10.3 - EX-10.3 - Jounce Therapeutics, Inc. | a2230618zex-10_3.htm |
| EX-10.1 - EX-10.1 - Jounce Therapeutics, Inc. | a2230618zex-10_1.htm |
| EX-5.1 - EX-5.1 - Jounce Therapeutics, Inc. | a2230618zex-5_1.htm |
| EX-3.2 - EX-3.2 - Jounce Therapeutics, Inc. | a2230618zex-3_2.htm |
| EX-3.1 - EX-3.1 - Jounce Therapeutics, Inc. | a2230618zex-3_1.htm |
| S-1/A - S-1/A - Jounce Therapeutics, Inc. | a2230618zs-1a.htm |
QuickLinks -- Click here to rapidly navigate through this document
Consent of Independent Registered Public Accounting Firm
We consent to the reference to our firm under the caption "Experts" and to the use of our report dated March 8, 2016, except for Note 1 and Note 16a as to which the date is November 17, 2016 and Note 16b as to which the date is January 17, 2017, in Amendment No. 1 to the Registration Statement (Form S-1 No. 333-215372) and related Prospectus of Jounce Therapeutics, Inc. dated January 17, 2017.
| /s/ Ernst & Young LLP | ||
Boston, Massachusetts January 17, 2017 |